Why BioMarin Pharmaceutical Inc.’s (BMRN) Stock Is Down 5.88%
As of Tuesday, November 03, BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 5.88%, which has investors questioning if this is right time to buy.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Jenna Brashear
Tudor Pop
Rosalio Madrigal
Michael Rose
| Share Statistics | BMRN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11,898.7 | $213.9 | 80% |
|
| Shares Out (Mil) | 193.6 | 55.4 | 75% |
|
| Institutional Ownership | 99.6% | 93.3% | 90% |
|
| Float (Mil) | 192.8 | 40.6 | 73% |
|
| Beta | 0.23 | 0.98 | 13% |
|
| Avg Daily Volume (000s) | 2,075 | 597 | 81% |
|
| Price Change (52-week) |
12.8% | 40.9% | 62% |
|
| Growth | BMRN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 11.6% | 13.2% | 64% |
|
| Net Income (5yr) | (16.4%) | (10.7%) | 24% |
|
| EPS (5yr) | (16.7%) | 15.5% | 17 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 10.4% | (15.7%) | 69% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 16 | 19 | 19 | |
| Current EPS | $0.893 | $3.028 | $6.344 | |
| Month Ago EPS | $1.720 | $3.673 | $6.543 | |
| # Rev Up | 0 | 2 | 0 | |
| # Rev Down | 3 | 1 | 1 | |
| Three Months Ago EPS | $1.737 | $5.026 | $6.496 | |
| Year/Year Chg | (240.9%) | 67.8% | 314.3% | |
| Financials | BMRN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3,655 | $39 | 69% |
|
| Net Income (TTM) (Mil) | ($19) | ($44) | 24% |
|
| EPS (TTM) | ($0.099) | ($1.400) | 35% |
|
| Operating Cash Flow (TTM) (Mil) | $677 | ($34) | 75% |
|
| Net Cash Flow (TTM) (Mil) | ($514) | $-0 | 5% |
|
| Long-Term Debt (Q1) (Mil) | $3,515 | $4 | 81% |
|
| Enterprise Value (Q1) (Mil) | $14,539 | $135 | 79% |
|
| Valuation | BMRN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.90 | 1.97 | 54% |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | BMRN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 53.2% | 67.9% | 65% |
|
| Net Margin | (0.5%) | (50.8%) | 30% |
|
| ROA | (0.2%) | (47.5%) | 37% |
|
| ROE | (0.3%) | (51.9%) | 34% |
|
| Liabilities to Assets | 45.9% | 29.7% | 37% |
|
| F-Score | 2 | 3 | 7% |
|
BioMarin Pharmaceutical Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors